Jian Huan1, Yi Gao2, Jing Xu3, Wenjiong Sheng3, Wei Zhu3, Shuyu Zhang4, Jianping Cao4, Jiang Ji1, Liyuan Zhang1, Ye Tian5. 1. Department of Radiotherapy and Oncology, The Second Affiliated Hospital of Soochow University Suzhou 215004, China. 2. Department of Gastroenterology, The Affiliated Jiangyin Hospital of Southeast University Jiangyin 214400, China. 3. School of Radiation Medicine and Protection and Jiangsu Provincial Key Laboratory of Radiation Medicine and Protection, Medical College of Soochow University Suzhou 215123, China. 4. School of Radiation Medicine and Protection and Jiangsu Provincial Key Laboratory of Radiation Medicine and Protection, Medical College of Soochow University Suzhou 215123, China ; Collaborative Innovation Center of Radiation Medicine of Jiangsu Higher Education Institutions, Soochow University Suzhou 215123, China. 5. Department of Radiotherapy and Oncology, The Second Affiliated Hospital of Soochow University Suzhou 215004, China ; Collaborative Innovation Center of Radiation Medicine of Jiangsu Higher Education Institutions, Soochow University Suzhou 215123, China.
Abstract
OBJECTIVE: Esophageal squamous cell carcinoma (ESCC) is one of the leading causes of cancer deaths worldwide. CD9 has been reported to play a critical role in cell motility, growth and metastasis of multiple cancers. The present study investigated the clinicopathological features of CD9, and its biological characteristics in ESCC. METHODS: Fifteen normal esophageal tissue specimens, fifty-three ESCC adjacent tissues and one hundred and four ESCC tissues were included in this study. Using immunohistochemistry (IHC), the expression levels of CD9 were evaluated among different samples. And its clinicopathological parameters and its prognostic factors were analyzed. Western blotting was used to measure CD9 expression and colony formation was performed to determine the effect of CD9 on cell growth in ESCC TE-1 cells. RESULTS: Compared with normal esophageal tissues and tumor adjacent tissues, CD9 expression level is significantly higher in ESCC tissues. CD9 expression correlated with tumor stage (P=0.022) and lymph node metastasis (P=0.019) in ESCC patients. Furthermore, the small interfering RNA-mediated silencing of CD9 expression in TE-1 cells resulted in increased proliferation as evidenced by increased colony number and colony size. CONCLUSION: CD9 expression is upregulated in ESCC tissues and its expression is correlated with tumor stage and lymph node metastasis in ESCC patients. CD9 suppresses the proliferation of TE-1 cells. CD9 may present a potential in tumor progression in ESCC.
OBJECTIVE:Esophageal squamous cell carcinoma (ESCC) is one of the leading causes of cancer deaths worldwide. CD9 has been reported to play a critical role in cell motility, growth and metastasis of multiple cancers. The present study investigated the clinicopathological features of CD9, and its biological characteristics in ESCC. METHODS: Fifteen normal esophageal tissue specimens, fifty-three ESCC adjacent tissues and one hundred and four ESCC tissues were included in this study. Using immunohistochemistry (IHC), the expression levels of CD9 were evaluated among different samples. And its clinicopathological parameters and its prognostic factors were analyzed. Western blotting was used to measure CD9 expression and colony formation was performed to determine the effect of CD9 on cell growth in ESCC TE-1 cells. RESULTS: Compared with normal esophageal tissues and tumor adjacent tissues, CD9 expression level is significantly higher in ESCC tissues. CD9 expression correlated with tumor stage (P=0.022) and lymph node metastasis (P=0.019) in ESCC patients. Furthermore, the small interfering RNA-mediated silencing of CD9 expression in TE-1 cells resulted in increased proliferation as evidenced by increased colony number and colony size. CONCLUSION:CD9 expression is upregulated in ESCC tissues and its expression is correlated with tumor stage and lymph node metastasis in ESCC patients. CD9 suppresses the proliferation of TE-1 cells. CD9 may present a potential in tumor progression in ESCC.
Authors: Susana Ovalle; María Dolores Gutiérrez-López; Nieves Olmo; Javier Turnay; María Antonia Lizarbe; Pedro Majano; Francisca Molina-Jiménez; Manuel López-Cabrera; María Yáñez-Mó; Francisco Sánchez-Madrid; Carlos Cabañas Journal: Int J Cancer Date: 2007-11-15 Impact factor: 7.396
Authors: Kathy S Wang; Haesook T Kim; Sarah Nikiforow; Alexander T Heubeck; Vincent T Ho; John Koreth; Edwin P Alyea; Philippe Armand; Bruce R Blazar; Robert J Soiffer; Joseph H Antin; Corey S Cutler; Jerome Ritz Journal: Blood Date: 2017-11-14 Impact factor: 22.113
Authors: S Yadavalli; S Jayaram; S S Manda; A K Madugundu; D S Nayakanti; T Z Tan; R Bhat; A Rangarajan; A Chatterjee; H Gowda; J P Thiery; P Kumar Journal: Sci Rep Date: 2017-03-06 Impact factor: 4.379
Authors: Kelly Pedrozo Ferreira; Bruna Cristine de Almeida; Laura Gonzalez Dos Anjos; Glauco Baiocchi; Fernando Augusto Soares; Rafael Malagoli Rocha; Edmund Chada Baracat; Andrey Senos Dobroff; Katia Candido Carvalho Journal: Int J Mol Sci Date: 2021-05-09 Impact factor: 5.923